阿立哌唑与利培酮治疗稳定期精神分裂症临床疗效评估

目的:通过跟踪随访,比较阿立哌唑与利培酮治疗稳定期精神分裂症的临床疗效及不良反应.方法:用阳性与阴性症状量表(PANSS)、社会功能缺陷筛选量表(SDSS)、日常生活能力量表(ADL)对稳定期精神分裂症患者进行评定.结果:入组时两组药物患者的PANSS各项分值在入组时无显著性差异(P＞0.05),6个月末PANSS减分率无显著性差异(P＞0.05).入组时两组药物患者的SDSS总分和ADL总分均无显著性差异(P＞0.05),6个月末利培酮组患者的ADL总分显著降低(P＞0.05),而阿立哌唑组患者的SDSS总分和ADL总分均显著降低(P＜0.01).药物不良反应方面,利培酮组锥体外系反应及对催乳素水平影响均明显高于阿立哌唑组.结论:对稳定期精神分裂症患者,两种药物对阳性与阴性症状的改善作用相当,但阿立哌唑组更能明显地改善社会功能和日常生活能力.

The clinical efficacy evaluation of aripiprazole and risperidone in the treatment of stable schizophrenia

Objective：By tracking the follow-up, comparing the clinical efficacy and adverse reactions of aripiprazole and risperidone in the treatment of stable schizophrenia . Methods ： With Positive And Negative Syndrome Scale （PANSS）, Social Disability Screening Scale （SDSS）, Activities of Daily Living （ADL） for stable schizophrenia patients were assessed. Results： Into the group of patients with two groups of drugs in PANSS scores no significant difference （ P 〉 0. 05）, 6 end of month PANSS reduction rate was no significant difference （ P 〈 0.05）. Two groups of drugs into the group of patients with SDSS total score and ADL total score was no significant difference （ P 〉 0. 05）, 6 end of month ADL total score in patients risperidone was significantly lower （ P 〈 0. 05）, while aripiprazole group of patients with SDSS total score and ADL total score were significantly lower （ P 〈 0. 01 ）. The adverse reactions of drugs, the risperidone group extrapyramidal reactions and effects on prolactin levels were significantly higher than the aripiprazole group. Conclusion： For stable schizophrenia patients, two kinds of drugs on positive and negative symptoms the improvement of the role quite, but the aripiprazole group improved significantly better social function and ability of daily life.